Research Topics
| K S SlobodSummaryAffiliation: St. Jude Children's Research Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Molecular evidence of ocular Epstein-Barr virus infectionK S Slobod
Departments of Infectious Diseases, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee, Memphis, Tennessee, TN, USA
Clin Infect Dis 31:184-8. 2000..Recognition of EBV-induced ocular disease as an initial presentation of clinical EBV infection is important to the practitioner because of the ubiquitous nature of this herpesvirus...
HIV vaccines: brief review and discussion of future directionsKaren S Slobod
Department of Infectious Diseases, St Jude Children s Research Hospital, MS 320 332 N Lauderdale, Memphis, TN 38105, USA
Expert Rev Vaccines 4:305-13. 2005..This article reviews data relevant to the development of cocktail vaccines which have been designed to elicit a wide range of envelope glycoprotein-specific B- and T-cell responses...
Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adultsKaren S Slobod
Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
Vaccine 22:3182-6. 2004..Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children...
Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1K S Slobod
Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA
Eur J Clin Microbiol Infect Dis 23:106-10. 2004..These findings have global implications because they support the consideration of recombinant vaccinia virus as a valuable HIV vaccine vector system...
Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategyJ Stambas
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
Vaccine 23:2454-64. 2005..Results highlight the D-V-P vaccination strategy as a promising approach for attaining durable, multi-isotype B-cell and T-cell activities toward HIV...
Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processingS Surman
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
Proc Natl Acad Sci U S A 98:4587-92. 2001..A likely explanation is that the physical location of the peptide within the native protein leads to differential antigen processing and consequent epitope selection...
Structural features of HIV envelope defined by antibody escape mutant analysisK S Slobod
Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 17:1205-9. 2001..This envelope configuration may provide an effective immune defense mechanism for HIV, as the highly variable residues of the V3 loop may shield conserved amino acids pertinent to viral infection...
Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtypeS A Brown
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
AIDS Res Hum Retroviruses 22:188-94. 2006..Results highlight the difficulty of predicting immune responses based on subtype alone and encourage considerations of antigenic disparity in addition to subtype disparity during HIV-1 vaccine design...
Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipientsK S Slobod
Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
Bone Marrow Transplant 28:573-80. 2001....
Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope proteinX Zhan
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
J Virol 77:4231-6. 2003..The results encourage the inclusion of more than one envelope in future vaccines to enhance the potential diversity and respective surveillance capacities of responding T-helper cell populations...
T cell immunotherapeutic populations control viral infections in bone marrow transplant recipientsK S Slobod
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
Immunol Res 24:289-301. 2001..The support of patients with T cell immunotherapies may ultimately revolutionize BMT, elevating the procedure from a salvage to a front-line treatment strategy for otherwise fatal disorders...
Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancerJ L Shenep
Department of Infectious Diseases, St Jude Children s Research Hospital, University of Tennessee Health Sciences Center, Memphis, TN 38105, USA
Clin Infect Dis 32:36-43. 2001..0). Results support the safety of oral cefixime therapy for low-risk febrile neutropenic children, a therapeutic approach that would facilitate earlier outpatient management and decrease the costs of treatment...
A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoproteinScott A Brown
Department of Immunology, Memphis, TN 38105, USA
J Virol 81:12535-42. 2007....
HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktailJulia L Hurwitz
Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
Front Biosci 13:609-20. 2008..The SJCRH multi-vectored, multi-envelope vaccine has now been shown to elicit HIV-1-specific B- and T-cell functions with a diversity and durability that may be required to prevent HIV-1 infections in humans...
HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulationsXiaoyan Zhan
Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 23:471-6. 2007..These results emphasized the important influence that envelope peptide position may have on antigen processing, and the consequent impact such processing may have on HIV-1-specific CD4(+) and CD8(+) T-cell activities...
Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BXiaoyan Zhan
Department of Infectious Diseases, St Jude Children s Research Hospital, 332N Lauderdale, Memphis, TN 38105, United States
Vaccine 25:8782-93. 2007..Together, experimental results encourage promotion of this recombinant SV construct as a vaccine candidate for the prevention of RSV in humans...
First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participantsJulia L Hurwitz
Department of Immunology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
AIDS 22:149-51. 2008..Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant...
Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIVXiaoyan Zhan
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
Vaccine 23:5306-20. 2005..The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives...
Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virusToru Takimoto
Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA
Viral Immunol 18:255-66. 2005..Sendai virus may prove an enormously valuable vaccine platform, permitting the delivery of recombinants targeting important pediatric respiratory pathogens, RSV chief among them...
Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsXiaoyan Zhan
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
Vaccine 26:3480-8. 2008..Results encourage the continued development of the candidate recombinant SeV vaccines to combat serious respiratory infections of children...
Application of the polyvalent approach to HIV-1 vaccine developmentJulia L Hurwitz
Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
Curr Drug Targets Infect Disord 5:143-56. 2005..Information presented in this review highlights the potential and importance of the polyvalent vaccine approach for the future development of an effective HIV-1 vaccine...
CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?Scott A Brown
Deparment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
Curr Drug Targets Infect Disord 5:113-9. 2005..Since CTL contribute to the success of vaccines in other model systems, an understanding of the strengths and possible limitations of these cells may be critical to future successes in the HIV-1 vaccine field...
HIV vaccine rationale, design and testingKaren S Slobod
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
Curr HIV Res 3:107-12. 2005..Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific B-cell and T-cell responses, are reviewed...
T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometryScott A Brown
Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 21:165-70. 2005..Results are consistent with the suggestion that gp120 peptide location influences antigen processing, which, in turn, influences the specificity of immunodominant T cells...
A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?Timothy D Lockey
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
AIDS Res Hum Retroviruses 18:1141-4. 2002..The remaining positions may be empty, or may be associated with a second, perhaps unrelated, peptide moiety...
Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cellsXiaoyan Zhan
Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
Vaccine 22:1206-13. 2004..Our results illustrate the flexibility and durability of immune responses toward individual components of mixed envelope vaccines and encourage the continued development of vaccine cocktails for the control of HIV...
Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activityScott A Brown
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
J Immunol 171:4140-8. 2003..To explain the clustering of Th cell epitopes, we propose that localization of peptide on exposed envelope surfaces facilitates proteolytic activity and preferential peptide shuttling through the Ag processing pathway...
Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSVToru Takimoto
St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
J Virol 78:6043-7. 2004..RSV G-recombinant SV is thus a promising live virus vaccine candidate for RSV...
The HIV pandemic: a forgotten crisis?Maxwell Madzikanga
HIV/AIDS Programme, Africa University, Old Mutare, Zimbabwe
Curr Drug Targets Infect Disord 5:85-6. 2005..The devastation caused by HIV and AIDS has touched virtually every world region. One concern is that the unrelenting nature of the HIV pandemic fosters a disposition, not of fear and determination, but of tolerance and complacency...
Research Grants
- Recombinant Sendai Virus as a Novel HIV Vaccine VectorKAREN SLOBOD; Fiscal Year: 2004..Studies described in this application may ultimately identify rSV as an effective intranasal vaccine vehicle useful in the prevention of HIV. ..
